Naftidrofuryl
 | |
|---|---|
| Systematic (IUPAC) name | |
| (RS)-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Legal status | ? |
| Routes | Oral |
| Identifiers | |
| CAS number | 31329-57-4  |
| ATC code | C04AX21 |
| PubChem | CID 4417 |
| ChemSpider | 4264 |
| UNII | 42H8PQ0NMJ |
| Chemical data | |
| Formula | C24H33NO3 |
| Mol. mass | 383.524 g/mol |
| SMILES
| |
| |
| (what is this?) (verify) | |
Naftidrofuryl (INN, also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate) is a drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic.[1] It may also be a 5-HT2 receptor antagonist. It is also licenced for the treatment of intermittent claudication due to peripheral arterial disease.
It is sold under the brand name Dusodril (Merck) and cerebromap for multiapex in middle east. It is also sold as Praxilene in the United Kingdom.[2]
Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[3]
Naftidrofuryl may be effective for relieving the pain of muscle cramps.[4]
References
- ↑ Reynolds, J.E.F. (ed.) (1993). Martindale: The extra pharmacopoeia (30th edition ed.). London: Pharmaceutical Press. p. 1310. ISBN 0-85369-300-5.
- ↑ http://www.patient.co.uk/medicine/naftidrofuryl
- ↑ http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm
- ↑ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
| |||||||||||||||||||||||||||||